This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
TLDR Biotech
The top stories in biotech & pharma, straight to your inbox in only one email.Trusted by 3000+ biotech and pharma professionals.
I consent to receive newsletters via email. Terms of use and Privacy policy.
Comprehensive daily coverage of the biotech and pharma industry, straight to your inbox.
Nov 17, 2026
•
3 min read
🧬 Isomorphic Labs raises $5B Series C, scaling AI drug design engine toward clinical trials, CG Oncology's (cretostimogene) hits Ph3 goal, cutting recurrence risk 68% in non-muscle invasive bladder cancer, Novartis' Cosentyx (secukinumab) wins FDA approval for polymyalgia rheumatica as first anti-IL-17 biologic following Ph3 trial
Nov 16, 2026
4 min read
🧬 Johnson & Johnson acquires Ollin Biosciences for $2.2B upfront to challenge Roche's Vabysmo in eye disease, FDA clears AstraZeneca's Imfinzi (durvalumab) plus Pfizer and Astellas' Padcev (enfortumab vedotin) for muscle-invasive bladder cancer following Ph3 success, Novo's (CagriSema) demonstrates over 20% weight loss at lower doses in Ph3 obesity trial
Nov 12, 2026
🧬 Pfizer secures $1.5B financing from Blackstone Life Sciences to fund obesity drug berobenatide development through 2028, FDA approves Merck KGaA's Pimjetmi (pimicotinib) targeting CSF-1R for tenosynovial giant cell tumour following Ph3 data, Amgen shares Ph3 data for (dazodalibep) targeting CD40L in systemic Sjögren's disease, showing strong ESSDAI improvements
Nov 10, 2026
🧬 PepGen's (PGN-EDODM1) Ph2 data show 46.5% splicing correction in myotonic dystrophy type 1, Bayer's Sunharbo (asundexian) wins FDA approval for secondary stroke prevention via Factor XIa inhibition, Oyster Therapeutics raises $60M Series A extension for tau-targeting brain drug development
Nov 9, 2026
🧬 Argenx to acquire Unnatural Products for up to $1.145B to expand macrocyclic peptide drug pipeline, Vir Biotechnology's (elebsiran/tobevibart) combination meets primary endpoint in Ph3 trial for chronic hepatitis D, J&J's (pasritamig) and (JNJ-9401) bispecific combo shows Ph1 promise in metastatic castration-resistant prostate cancer
Nov 6, 2026
🧬 Eli Lilly, Hims & Hers partner to expand US access to obesity drugs Zepbound and Foundayo, Johnson & Johnson's Rybrevant (amivantamab) wins FDA accelerated approval for recurrent or metastatic head and neck squamous cell carcinoma, Moderna reports 29% revenue growth to $1.3B, driven by global COVID vaccine uptake
Nov 5, 2026
🧬 Revolution Medicines' Rasonque posts $198M in Q3, hailed as best oncology drug launch in history, AstraZeneca reportedly offers $10B to acquire Rhythm Pharmaceuticals, targeting rare obesity drug Imcivree, ANI Pharmaceuticals to acquire Egetis Therapeutics for $560M, boosting rare thyroid hormone disorder drug Emcitate
Nov 4, 2026
🧬 Novo raises full-year outlook after oral Wegovy quarterly sales hit $812M, beating expectations, Boehringer Ingelheim, Sino Biopharmaceutical partner on six oncology biologics, $358M upfront, $7B milestones, AbbVie invests £120M ($160M) in UK, launching new Oxford R&D site expanding immunology, neuroscience, oncology capabilities
Nov 3, 2026
🧬 Lonza acquires five Merck KGaA US manufacturing facilities for mid-triple-digit millions CHF, boosting ADC capabilities, Pfizer raises 2026 annual revenue guidance to $62B–$64B on strong commercial performance and cost cuts, Bayer pharma unit hits "turning point" with 8% Q3 sales growth, raises full-year outlook